Sarepta Therapeutics Reports Q2 2026 Financial Results

What Happened
On August 5, 2026, Sarepta Therapeutics, Inc. announced its financial results for the quarter ended June 30, 2026 and furnished the full press release as Exhibit 99.1 to a Current Report on Form 8‑K (Item 2.02). The filing was signed by CEO Michael Severino, M.D.

Key Details

• Press release announcing quarterly results dated August 5, 2026 was furnished as Exhibit 99.1 to the Form 8‑K.
• Results cover the quarter ended June 30, 2026 (quarterly results / earnings disclosure).
• The Form 8‑K was filed under Item 2.02 (Results of Operations and Financial Condition) and includes exhibit references under Item 9.01.
• The report is signed by Sarepta’s CEO, Michael Severino, M.D.

Why It Matters
This 8‑K signals Sarepta has publicly released its latest quarterly earnings and other financial information; investors should review the attached press release for revenue, profit/loss, cash position, guidance and any pipeline or operational updates. The Form 8‑K itself furnishes the press release but does not replace reviewing the full release and subsequent filings (e.g., 10‑Q) for detailed financial statements and commentary.